tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Tarsus Pharmaceuticals (TARS) and Oak Street Health (OSH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cogent Biosciences (COGTResearch Report), Tarsus Pharmaceuticals (TARSResearch Report) and Oak Street Health (OSHResearch Report) with bullish sentiments.

Cogent Biosciences (COGT)

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $23.00. The company’s shares closed last Wednesday at $5.55, close to its 52-week low of $5.15.

According to TipRanks.com, Slutsky is a 1-star analyst with an average return of -3.4% and a 38.7% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics, Catalyst Biosciences, and Sierra Oncology.

Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $22.67, which is a 309.9% upside from current levels. In a report issued on March 15, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

Tarsus Pharmaceuticals (TARS)

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Tarsus Pharmaceuticals on March 15 and set a price target of $69.00. The company’s shares closed last Wednesday at $17.13, close to its 52-week low of $14.41.

According to TipRanks.com, Dolezal is ranked 0 out of 5 stars with an average return of -12.4% and a 20.7% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Larimar Therapeutics, and Oyster Point Pharma.

Currently, the analyst consensus on Tarsus Pharmaceuticals is a Moderate Buy with an average price target of $54.50, a 200.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.

Oak Street Health (OSH)

Robert W. Baird analyst Vikram Kesavabhotla maintained a Buy rating on Oak Street Health yesterday and set a price target of $26.00. The company’s shares closed last Wednesday at $21.14, close to its 52-week low of $13.72.

According to TipRanks.com, Kesavabhotla ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.8% and a 37.7% success rate. Kesavabhotla covers the Technology sector, focusing on stocks such as Definitive Healthcare Corp, Tabula Rasa HealthCare, and InnovAge Holding.

Currently, the analyst consensus on Oak Street Health is a Strong Buy with an average price target of $32.42, which is a 60.5% upside from current levels. In a report released today, Cowen & Co. also upgraded the stock to Buy with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COGT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed